References
- Cancer in Slovenia 2016 Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2019.
- Zakotnik B, Zadnik Z, Žagar T, Primic Žakelj M, Ivanuš U, Jerman T, et al. Reaching sustainable oncology care via the National Cancer Control Program (NCCP). Ann Oncol 2019; 30(Suppl 5): v671-82. doi: 10.1093/annonc/mdz263
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): colon cancer. Version 1.2020. [cited 2020 Feb 28]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon_cancer.pdf
- Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-422. doi: 10.1093/annonc/mdw235
- Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. Eur J Cancer 2019; 109: 70-83. doi: 10.1016/j.ejca.2018.12.019
- Patel JN, Fon MK, Jagosky M. Colorectal cancer biomarkers in the era of personalized medicine. J Pers Med 2019; 9(1). doi: 10.3390/jpm9010003
- Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015; 21:1350-6. doi: 10.1038/nm.3967
- Rebersek M, Mesti T, Boc M, Ocvirk J. Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients. Radiol Oncol 2019; 53: 85-95. doi: 10.2478/raon-2019-0013
- Afrasanie VA, Marinca MV, Alexa-Stratulat T, Păduraru M I, Adavidoaiei AM, Miron L, et al. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician. Radiol Oncol 2019; 53: 265-74. doi: 10.2478/raon-2019-0033
- Inamura K. Colorectal cancers: an update on their molecular pathology. Cancers 2018; 10: pii: E26. doi: 10.3390/cancers10010026
- Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 2017; 17: 79-92. doi: 10.1038/nrc.2016.126
- Fontana E, Eason K, Cervantes A, Salazar, R, Sadanandam A. Context matters - consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Ann Oncol 2019; 30: 520-7. doi: 10.1093/annonc/mdz052
- Thanki K, Nicholls ME, GajjarA, Senagore AJ, Qiu S, Szabo C, et al. Consensus molecular subtypes of colorectal cancer and their clinical implications. Int Biol Biomed J 2017; 3: 105-11. PMID: 28825047
- Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res 2018; 24: 1062-72. doi: 10.1158/1078-0432.CCR-17-2484
- Dienstmann R, Salazar R, Tabernero J. Molecular subtypes and the evolution on of treatment decisions in metastatic colorectal cancer. Am Soc Clin Oncol Educ Book 2018; 38: 231-8. doi: 10.1200/EDBK_200929
- Kato S, Schwaederle MC, Fanta PT, Okamura R, Leichman L, Lippman SC, et al. Genomic assessment of blood- derived circulating tumor DNA in patients with colorectal cancers: Correlation with tissue sequencing, therapeutic response, and survival. JCO Precis Oncol 2019; 3: 1-25. doi: 10.1200/PO.18.00158
- Siena S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, Smith D, Tabernero J, et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann Oncol 2018; 29: 119-26. doi: 10.1093/annonc/mdx504
- Lenz, HJ, Ou FS, Venook, AP, Hochster HS, Niedzwiecki D, Richard M, et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance). J Clin Oncol 2019; 37: 1876-85. doi: 10.1200/JCO.18. 02258
- Aderka D, Stintzing S, Heinemann V. Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. Lancet Oncol 2019; 20: e274-83. doi: 10.1016/S1470-2045(19)30172-X
- Stintzing S, Wirapati P, Lenz HJ, Neureiter D, Fischer von Weikersthal L, Decker T, et al. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and 1st-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Ann Oncol 2019; 30: 1796-803. doi: 10.1093/annonc/mdz387
- Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol 2019; 16: 690-704. doi: 10.1038/s41575-019-0209-8